AdaptHealth (AHCO) Q4 2022: Sleep Patient Census Hits New High as Diabetes Growth Slows to Low Teens
AdaptHealth’s record sleep patient census underscores durable recurring revenue, but diabetes growth deceleration and cost inflation reshape the 2023 outlook. Management leans on operational leverage and cost initiatives to offset mix and payer headwinds. Guidance embeds conservatism for persistent inflation, with market share gains in sleep a key upside lever.
Summary
- Sleep Market Share Expansion: Record PAP patient census signals lasting recurring revenue and improved competitive positioning.
- Diabetes Growth Deceleration: Lower payer mix and volume pressure narrows segment outlook, impacting 2023 targets.
- Cost Structure Reset: Management embeds inflation and supply chain costs into guidance while launching new cost control initiatives.
Business Overview
AdaptHealth (AHCO) is a nationwide provider of home medical equipment and services, specializing in sleep, respiratory, diabetes, and supplies for patients at home. The company’s business model is anchored by recurring revenue, especially in sleep apnea, respiratory therapy, and ongoing medical supplies. Major segments include sleep (CPAP and supplies), diabetes (continuous glucose monitors, insulin pumps), respiratory, and home medical equipment (HME). Revenue is generated through a mix of rentals (high-margin, recurring), sales, and resupply orders, with a focus on scaling patient census to drive long-term cash flow.
Performance Analysis
AdaptHealth delivered double-digit top-line growth for both the full year and the fourth quarter, with sleep products leading non-acquired revenue gains. Sleep patient census reached a new record, surpassing pre-recall levels, reflecting both pent-up demand and successful market share capture. However, gross margin pressure persisted, as the company intentionally incurred extra labor and supply chain costs to accelerate patient setups and capitalize on the Philips recall-driven demand surge.
Diabetes segment growth slowed to the low teens, below initial expectations, due to a shift in payer mix toward lower-reimbursing government plans and a moderation in new patient starts. Rental revenue mix underperformed expectations, impacting margins, as sales revenue (lower margin) made up a higher proportion of the portfolio. On the cost side, unexpected inflation and payer recoupments trimmed EBITDA, while investments in technology and supply chain infrastructure weighed on near-term profitability but supported higher operating cash flow. Free cash flow conversion was muted by elevated capital expenditures, as equipment purchases remained above historical norms to work through the PAP backlog and support census growth.
- Sleep Segment Drives Recurring Revenue: Record PAP census positions AdaptHealth for durable resupply and rental streams.
- Diabetes Growth Misses Initial Targets: Payer mix shift toward government plans and slowing starts pressured segment expansion.
- Inflation and Supply Chain Headwinds: Higher raw material, freight, and labor costs—plus payer recoupments—compressed margins and required downward guidance revisions.
Operational leverage is expected to improve in 2023, with management targeting a margin recovery through cost discipline and supply chain rationalization, though near-term growth is tempered by diabetes and rental mix challenges.
Executive Commentary
"Driving this growth was our ability to source and deliver CPAP devices to satisfy the demand that is built up as a result of the Phillips recall. These efforts, including extra labor and other extraordinary costs, contributed to the decline in our 2022 gross margin. But we intentionally incurred those costs as part of our plan to increase market share through the accelerated pace of patient setups."
Steve Griggs, Chief Executive Officer
"Our guidance for adjusted EBITDA is $650 million to $710 million, representing 14.5% growth over 2022. The midpoint adjusted EBITDA margin of 21.3% is up from 20.0% in 2022... We are in process of installing new cost management initiatives focused on revamping our supply chain infrastructure, rationalizing our real estate footprint, and consolidating various supplier agreements into national contracts to leverage our buying power."
Jason Clements, Chief Financial Officer
Strategic Positioning
1. Sleep Census Scale and Recurring Revenue Engine
AdaptHealth’s record PAP patient census reflects successful execution in capturing patients during a period of constrained industry supply. This expanded base is critical, as once a patient is set up on a device, recurring rental and resupply revenue streams are highly predictable. Management sees this as a durable competitive advantage, with resupply census also at record levels, providing multi-year revenue visibility.
2. Technology-Driven Efficiency and Patient Engagement
The company is aggressively investing in digital infrastructure, with ePrescribe, payer portals, and the MyApp mobile platform driving administrative efficiency and patient connectivity. Over 30,000 MyApp downloads and growing digital order penetration signal traction, and the technology suite is positioned to lower cost-to-serve and enable value-based care pilots.
3. Diabetes Segment Under Pressure from Payer Mix
Diabetes growth decelerated faster than anticipated, with a shift toward government payers (lower reimbursement) and a moderation in new starts. Management expects this trend to persist, with diabetes non-acquired growth guided to high single digits for 2023 and longer-term glide path to mid/high single digits, pressuring overall growth but partially offset by acquired growth levers.
4. Cost and Supply Chain Reset
Inflation and supply chain disruptions forced AdaptHealth to overhaul its cost structure, including centralized distribution and locked-in purchasing agreements (often at a premium). New cost management initiatives—supply chain rationalization, real estate optimization, and supplier consolidation—are underway, though not yet baked into 2023 guidance, offering potential upside if execution is strong.
5. M&A and Capital Allocation Discipline
Limited acquisitions in 2022 provided little contribution, but management expects to deploy the bulk of 2023 free cash flow toward incremental M&A, targeting tuck-ins to supplement organic growth and offset diabetes headwinds. Leverage remains manageable, with no revolver balance and improved operating cash flow supporting flexibility.
Key Considerations
AdaptHealth’s 2022 performance was defined by aggressive patient capture in sleep, offset by diabetes deceleration and persistent cost inflation. As the company pivots to 2023, the focus is on operational leverage, technology-driven efficiency, and targeted M&A to sustain growth ambitions.
Key Considerations:
- Recurring Revenue Moat: High patient census in sleep and supplies creates stable, multi-year revenue streams.
- Diabetes Payer Mix Drag: Shift to government payers reduces segment margin and narrows upside, requiring growth from other categories or acquisitions.
- Cost Control Initiatives: Supply chain and real estate rationalization, plus supplier consolidation, are positioned as margin levers but have not yet contributed to guidance.
- Technology Adoption: MyApp and digital order penetration are early but promising steps toward lower cost-to-serve and improved patient engagement.
- Guidance Embedded Conservatism: Management has built inflation, supply chain, and payer headwinds into the 2023 outlook, aiming to avoid further downward revisions.
Risks
Persistent cost inflation, payer recoupments, and ongoing diabetes mix shifts remain material risks to margin and growth targets. Execution on cost management programs is unproven, and failure to realize savings could limit margin expansion. Regulatory changes or reimbursement cuts, particularly in government payer programs, could further pressure top-line and EBITDA. Competitive intensity in sleep and diabetes, especially as supply chain normalizes, may test AdaptHealth’s market share gains.
Forward Outlook
For Q1 2023, AdaptHealth guided to:
- Non-acquired growth of 6.5% to 7%, with sequential improvement expected as sales incentives and cost initiatives ramp.
- EBITDA margin profile similar to Q1 2022, with margin expansion expected over the year.
For full-year 2023, management maintained guidance:
- Net revenue of $3.16 billion to $3.24 billion, 7.7% non-acquired growth.
- Adjusted EBITDA of $650 million to $710 million, with margin expansion to 21.3% at the midpoint.
- CapEx at 10–12% of revenue, front-loaded to address PAP backlog.
Management highlighted:
- Cost management initiatives not included in guidance, with updates expected in Q1 2023.
- Diabetes segment growth to high single digits, sleep growth above long-term trend, and incremental M&A as a use of free cash flow.
Takeaways
AdaptHealth’s record sleep census and recurring revenue base provide a foundation for stability, but diabetes headwinds and cost inflation have reset near-term growth and margin expectations.
- Patient Census as Growth Engine: Sleep and resupply census records support recurring revenue, but pace of new setups will determine medium-term trajectory.
- Margin Recovery Hinges on Execution: Cost control and supply chain rationalization are critical for offsetting mix and inflation headwinds in 2023.
- Watch for M&A and Digital Leverage: Incremental acquisitions and technology adoption could become key drivers if organic growth slows further.
Conclusion
AdaptHealth enters 2023 with a strong recurring revenue base and operational scale, but faces a more challenging margin and growth environment due to diabetes deceleration and persistent cost pressures. Success will depend on delivering cost savings, sustaining sleep market share, and judicious capital deployment.
Industry Read-Through
AdaptHealth’s experience highlights sector-wide challenges in home medical equipment, including cost inflation, supply chain volatility, and payer mix shifts—especially in diabetes and sleep. Recurring revenue models offer resilience, but margin pressure from labor, freight, and reimbursement dynamics is likely to persist for peers. Technology adoption (ePrescribe, patient apps) is becoming table stakes, and companies able to leverage digital platforms for efficiency and engagement may pull ahead. Market share shifts in sleep suggest that supply chain agility and patient acquisition speed are critical differentiators, a dynamic that will continue as the industry normalizes post-recall and pandemic.